PsA: IL23 Inhibition

Targeting IL-23 a Hit in Psoriatic Arthritis

Multiple disease domains showed significant improvement

Guselkumab Improves Psoriatic Arthritis in Phase 2a Study

Guselkumab significantly improved joint symptoms, physical function, psoriasis, enthesitis, dactylitis and…

Selective IL-23 Inhibitor Shines in Mid-Stage PsA Trial

Risankizumab broadly effective against joint and skin symptoms

Risankizumab may improve joint and skin symptoms in PsA patients

Results of a dose-ranging phase II trial support further…